Compounded GLP-1s and the FDA in 2026 — Where Things Actually Stand
A lot of articles about compounded semaglutide and tirzepatide are over-stating what the FDA has actually done. Here's the timeline, what each action actually changed, and what's still legal in May 2026 — written carefully because the regulatory framework is genuinely the patient-safety story.
The verified timeline (May 2026)
- December 2024FDA resolved the tirzepatide shortage. Compounding under the shortage exception for tirzepatide ended.
- February 2025FDA resolved the semaglutide shortage. The 503A grace period ended April 22, 2025; the 503B grace period ended May 22, 2025.
- November 2025The Trump-Novo Nordisk deal made branded Ozempic available at approximately $245/month for eligible Medicare, Medicaid, and TrumpRx patients.
- December 2025FDA approved oral Wegovy 25mg for weight management.
- February 2026FDA press release: "FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs," targeting operators making essentially-copies under no proper compounding pathway.
- March 3, 2026FDA issued 30 warning letters. Hims/Hers shifted to branded GLP-1s under a Novo Nordisk partnership.
- April 30, 2026FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. Public comment period open through June 29, 2026.
- May 2026Amazon launched same-day Ozempic delivery in 3,000+ U.S. cities. NHWL continues to dispense compounded preparations under the 503(a) patient-specific pathway.
What each action actually changed (and didn't)
The shortage resolution (2024–2025)
During the FDA-declared shortages, both 503(a) and 503(b) pharmacies could compound semaglutide and tirzepatide more broadly. When the shortages were resolved, that broader exception ended. 503(a) patient-specific compounding remained legal under the existing FD&C framework — not as a shortage exception, but as the ordinary 503(a) pathway when compounds are clinically distinct from FDA-approved finished drugs (different dose, different concentration, or an additional ingredient creating a meaningfully different preparation).
The February 2026 press release and warning letters
The FDA's "intends to take action" announcement targeted operators making essentially-copies of brand-name GLP-1 drugs without proper pathway justification. The 30 warning letters in March 2026 went to specific operators identified as non-compliant. Reputable 503(a) pharmacies operating with patient-specific prescriptions and documented clinical rationale weren't the target.
The April 30, 2026 503B Bulks proposal
This is the action most often misunderstood in news coverage. The FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List — the list of bulk active ingredients that 503(b) outsourcing facilities are allowed to compound. It is a proposed rule, in public comment through June 29, 2026.
What it affects: 503(b) outsourcing facilities producing semaglutide and tirzepatide as bulk-batch preparations.
What it does not affect: 503(a) patient-specific compounding for individual patients under valid prescriptions with documented clinical justification.
What "patient-specific" means in practice
503(a) patient-specific compounding requires:
- A documented clinical evaluation (Dr. Sharma reviews each patient's medical history).
- A prescription written by the licensed physician for that patient.
- A clinically meaningful difference from any FDA-approved finished drug — different dose, different concentration, or an additional ingredient that creates a distinct preparation.
- A state-licensed 503(a) pharmacy preparing the compound under USP 797/800 sterility standards.
- Records traceable from the prescription to the dispensed product.
NHWL prescriptions are written this way as standard practice. The clinical justification is documented in the patient's record. The pharmacy name is on the invoice. This is the framework that the 2026 FDA actions did not change.
What might happen next (and what we're watching)
- June 29, 2026: public comment period closes on the 503B Bulks proposal. Final rule may follow.
- Continued enforcement against bad actors: the FDA is signaling continued action against operators making essentially-copies. We expect more warning letters and possible injunctions targeting offshore peptide vendors and gray-market sellers.
- Possible state-level changes: some state pharmacy boards may add their own restrictions. We track California Board of Pharmacy guidance closely.
- Further branded price changes: Novo Nordisk and Eli Lilly continue to adjust pricing in response to political and competitive pressure. The price gap between branded and compounded may narrow over the next 12-24 months.
What this means for NHWL patients
- Operationally, no change. Continue with your protocol. The pathway we use is unaffected.
- The pharmacy name remains transparent. Ask for it; it's on your invoice.
- The COA remains available on request. Ask if you want to see it.
- If your circumstances change (gain insurance coverage for branded, become eligible for TrumpRx pricing, etc.), we'll discuss whether brand-name is the better path.
What this means if you're considering treatment
- Verify the provider operates under 503(a) patient-specific compounding, not gray-market peptide sourcing.
- Verify physician oversight is real — a documented evaluation, not a 30-second form check.
- Ask which pharmacy. If they won't say, walk away.
- Compare cash price with whatever insurance options exist for branded GLP-1; choose the path with the better clinical and financial fit.
Frequently asked questions
Did the FDA ban compounded semaglutide in 2026?
No. The FDA-declared shortages of semaglutide and tirzepatide ended in February 2025 and December 2024 respectively, ending the broader compounding exception. The April 30, 2026 FDA proposal to remove semaglutide and tirzepatide from the 503B Bulks List is in public comment through June 29, 2026, and affects 503(b) outsourcing — not 503(a) patient-specific compounding.
Is compounded semaglutide still legal in May 2026?
Yes, when prepared by a state-licensed 503(a) pharmacy for an individual patient under a valid prescription with documented clinical justification (a different dose, different concentration, or added ingredient like B12). This is what NHWL operates under.
What changed in the FDA's 2026 actions?
The 2026 actions tightened oversight of operators making essentially-copies of brand-name drugs. The Feb 2026 press release, the March 2026 warning letters, and the April 30 503B Bulks proposal all target operators producing semaglutide and tirzepatide as commodity products. Patient-specific 503(a) compounding with proper documentation continues.
What does this mean for me as a patient?
For NHWL patients, nothing operational changes. For patients getting compounded GLP-1 from sketchier sources, this is a good moment to verify the pharmacy is U.S.-licensed and the prescription is patient-specific.
Should I switch to brand-name to be safe?
It's the right move if your insurance covers it, your out-of-pocket is comparable, or you have a specific reason to prefer the FDA-approved finished product. Otherwise, properly-supervised 503(a) compounded therapy remains a reasonable alternative.
This article is informational only and not medical advice. Speak with a licensed physician before starting any GLP-1 therapy. Citations: FDA Press Release "FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize" (https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize); FDA proposed rule on 503B Bulks List (April 30, 2026, public comment through June 29, 2026); Pharmacy Times (May 2026); ArentFox Schiff legal alert (Feb 2026). Wegovy®, Ozempic® are registered trademarks of Novo Nordisk A/S; Mounjaro®, Zepbound® are registered trademarks of Eli Lilly and Company. New Hope Weight Loss is not affiliated with, endorsed by, or sponsored by these companies.